Galapagos appoints Piet Wigerinck as Senior VP Development
Galapagos NV announced the appointment of Dr. Piet Wigerinck as Senior Vice President of Development. As a member of Galapagos' Executive Team, Dr. Wigerinck will oversee the development of Galapagos' drug candidates, including pre-clinical development, chemistry manufacturing & control (CM&C), regulatory aspects, and clinical development.
Dr. Piet Wigerinck joins Galapagos from Tibotec in Belgium (a subsidiary of Johnson & Johnson) where he was VP Drug Discovery, Early Development and CM&C, and a member of the Management Board. He started his professional career as a medicinal chemist at Janssen Research Foundation in 1992. He then joined Tibotec in 1998, where, under his leadership, TMC114 (PrezistaTM) was selected and moved forward into clinical trials. Dr. Wigerinck also played a key role in Tibotec's expansion into novel diseases such as Hepatitis C and advanced several compounds into Phase I and Phase II clinical trials. He brings over 15 years of research and development experience from both big pharma and biotech to Galapagos. Piet Wigerinck holds a PhD from the K.U. Leuven and is inventor on more than 25 patent applications.
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.